A recent study has unveiled a significant rise in the number of adults in Ontario prescribed stimulant medications for ADHD, particularly among women, in the aftermath of the COVID-19 pandemic. The findings, published in the Canadian Medical Association Journal, reveal that over 220,000 adults filled prescriptions for stimulants such as Vyvanse and Concerta from March 2020 to March 2024, a dramatic increase from approximately 107,000 in the preceding four years. This trend raises critical questions about the changing landscape of ADHD diagnoses and treatment.
A Dramatic Increase in Prescriptions
The research highlights a notable dip in stimulant prescriptions immediately following the onset of the pandemic, as healthcare services adapted to unprecedented challenges. However, this was soon followed by a sharp rebound, particularly among women, who constituted 59 per cent of new adult stimulant users in the pandemic period, compared to 48 per cent prior. “We don’t often see this rapid growth in a drug class, especially one that has been established for so long,” remarked Mina Tadrous, a pharmacist and researcher at the University of Toronto. “We need to pay attention to this trend.”
The rise in stimulant prescriptions for ADHD aligns with broader observations of an increase in adult diagnoses, particularly among women. A previous study published in JAMA Network Open corroborated these findings, indicating a significant uptick in prescriptions across Ontario. Similar patterns have emerged from studies in the United States, the UK, and various European countries, underscoring a global phenomenon.
Telemedicine: A New Route to Diagnosis
The shift to virtual healthcare during the pandemic has transformed the landscape of ADHD diagnosis and treatment. Daniel Myran, a research chair in family and community medicine at North York General Hospital, noted a surge in young adults seeking stimulant prescriptions after receiving ADHD diagnoses from for-profit telemedicine clinics. The CMAJ study revealed that 29 per cent of new patients obtained their prescriptions via virtual consultations after March 2020, a stark contrast to the negligible numbers before the pandemic, when telemedicine was rarely utilised in Canada.
“This can be done very quickly from the comfort of your home,” Dr. Myran explained. “While this accessibility can facilitate accurate diagnoses for those genuinely struggling with ADHD, it also raises concerns about potential overdiagnosis.” The implications of overdiagnosis are particularly concerning, as stimulants, while effective in enhancing attention and focus, carry risks. Long-term use can lead to cardiovascular issues, and inappropriate prescriptions may trigger manic episodes in individuals with pre-existing mental health conditions.
The Role of Social Media in Raising Awareness
The pandemic’s shift to digital living may have also contributed to a real increase in ADHD symptoms, according to some researchers. The proliferation of content on social media platforms, especially TikTok, has heightened awareness of ADHD and its symptoms. Influencers sharing their experiences have likely encouraged many to consider whether they, too, might be affected by the disorder.
Emma Climie, a psychologist and associate professor at the University of Calgary, emphasised that the highest rates of new ADHD diagnoses are now observed in women in their 30s and 40s. She, alongside colleague Brandy Callahan, is conducting a long-term study focused on adult women with ADHD. Many women become aware of their symptoms after their children receive diagnoses, as ADHD has a genetic component. Climie noted that for some women, the coping mechanisms they relied on in youth may falter under the pressures of demanding jobs and family responsibilities. “They’re burned out, they’re exhausted,” she stated. “They struggle with feelings of inadequacy, wondering why it seems everyone else has their life together while they feel overwhelmed.”
Why it Matters
The substantial increase in ADHD diagnoses and stimulant prescriptions among adults, particularly women, has profound implications for mental health care in Ontario and beyond. It reveals the necessity for a nuanced understanding of ADHD, especially in demographics that have historically been overlooked. As awareness grows and diagnostic pathways evolve, it is imperative for healthcare providers to balance accessibility with caution, ensuring that individuals receive appropriate diagnoses and treatments without falling prey to the risks of overdiagnosis. This evolving landscape calls for ongoing research and dialogue to better support those navigating the complexities of ADHD in their lives.
